PRELUDE THERAPEUTICS INC Capital Expenditures Incurred but Not yet Paid
PRELUDE THERAPEUTICS INC (PRLD) reported Capital Expenditures Incurred but Not yet Paid of $28.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was $28.00K.
- PRELUDE THERAPEUTICS INC capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- PRELUDE THERAPEUTICS INC capital expenditures incurred but not yet paid for the quarter ending 2025-06-30 was -$19.00K.
- PRELUDE THERAPEUTICS INC capital expenditures incurred but not yet paid for the quarter ending 2025-03-31 was $19.00K.
- PRELUDE THERAPEUTICS INC capital expenditures incurred but not yet paid for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- PRELUDE THERAPEUTICS INC capital expenditures incurred but not yet paid for fiscal 2024 was $10.00K, a 93.87% decline from fiscal 2023.
- PRELUDE THERAPEUTICS INC capital expenditures incurred but not yet paid for fiscal 2023 was $163.00K, a 81.11% increase from fiscal 2022.
- PRELUDE THERAPEUTICS INC capital expenditures incurred but not yet paid for fiscal 2022 was $90.00K, a 88.83% decline from fiscal 2021.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-06-30 | $28.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $28.00K 10-Q · filed 2026-08-11 | ||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $0.00 10-K · filed 2026-03-10 | |||
| 2025-06-30 | -$19.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | ||
| 2025-03-31 | $19.00K 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | $10.00K 10-K · filed 2026-03-10 | |||
| 2023-12-31 | -$91.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $133.00K derived: sum of 2 quarters · filed 2025-03-10 | $142.00K derived: sum of 3 quarters · filed 2025-03-10 | $163.00K 10-K · filed 2025-03-10 |
| 2023-09-30 | $224.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $233.00K derived: sum of 2 quarters · filed 2023-11-01 | $254.00K 10-Q · filed 2023-11-01 | $21.00K derived: sum of 4 quarters · filed 2024-02-15 |
| 2023-06-30 | $9.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $30.00K 10-Q · filed 2023-08-03 | -$203.00K derived: sum of 3 quarters · filed 2024-02-15 | $43.00K derived: sum of 4 quarters · filed 2024-02-15 |
| 2023-03-31 | $21.00K 10-Q · filed 2023-05-08 | -$212.00K derived: sum of 2 quarters · filed 2024-02-15 | $34.00K derived: sum of 3 quarters · filed 2024-02-15 | -$243.00K derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-12-31 | -$233.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $13.00K derived: sum of 2 quarters · filed 2024-02-15 | -$264.00K derived: sum of 3 quarters · filed 2024-02-15 | $90.00K 10-K · filed 2024-02-15 |
| 2022-09-30 | $246.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | -$31.00K derived: sum of 2 quarters · filed 2023-11-01 | $323.00K 10-Q · filed 2023-11-01 | $1.03M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | -$277.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $77.00K 10-Q · filed 2023-08-03 | $786.00K derived: sum of 3 quarters · filed 2023-08-03 | $497.00K derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $354.00K 10-Q · filed 2023-05-08 | $1.06M derived: sum of 2 quarters · filed 2023-05-08 | $774.00K derived: sum of 3 quarters · filed 2023-05-08 | $1.07M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $709.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $420.00K derived: sum of 2 quarters · filed 2023-03-15 | $720.00K derived: sum of 3 quarters · filed 2023-03-15 | $806.00K 10-K · filed 2023-03-15 |
| 2021-09-30 | -$289.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $11.00K derived: sum of 2 quarters · filed 2022-11-14 | $97.00K 10-Q · filed 2022-11-14 | $772.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $300.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $386.00K 10-Q · filed 2022-08-09 | $1.06M derived: sum of 3 quarters · filed 2022-08-09 | $1.08M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $86.00K 10-Q · filed 2022-05-10 | $761.00K derived: sum of 2 quarters · filed 2022-05-10 | $778.00K derived: sum of 3 quarters · filed 2022-05-10 | $818.00K derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $675.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $692.00K derived: sum of 2 quarters · filed 2022-03-17 | $732.00K derived: sum of 3 quarters · filed 2022-03-17 | $765.00K 10-K · filed 2022-03-17 |
| 2020-09-30 | $17.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $57.00K derived: sum of 2 quarters · filed 2021-11-12 | $90.00K 10-Q · filed 2021-11-12 | $48.00K derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $40.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $73.00K 10-Q · filed 2021-08-12 | $31.00K derived: sum of 3 quarters · filed 2021-08-12 | |
| 2020-03-31 | $33.00K 10-Q · filed 2021-05-11 | -$9.00K derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2019-12-31 | -$42.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $66.00K 10-K · filed 2021-03-16 | ||
| 2019-09-30 | $108.00K 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |